This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow
by Nalak Das
Although corporate earnings growth was negative year over year in the first three quarters of last year, fourth-quarter results have been faring better than initially anticipated.
Shopify (SHOP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Shopify (SHOP) delivered earnings and revenue surprises of 86.96% and 4.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lithia Motors (LAD) Lags Q4 Earnings Estimates
by Zacks Equity Research
Lithia Motors (LAD) delivered earnings and revenue surprises of -4.22% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Barrick Gold (GOLD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Barrick Gold (GOLD) delivered earnings and revenue surprises of 21.43% and 0.84%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chimera (CIM) delivered earnings and revenue surprises of 25.49% and 20.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment
by Zacks Equity Research
The Eco-Flex Teat Dip launch is likely to expand Ecolab's (ECL) Food & Beverage product portfolio.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $237.09 in the latest trading session, marking a -1.52% move from the prior day.
Best Thematic ETFs for 2020: Cloud, Internet of Things & More
by Neena Mishra
Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.